



CHANGE THE GAME FOR EGFR EXON 20 INSERTION MUTATED NON-SMALL CELL LUNG CANCER (NSCLC)

NEW AND NOW APPROVED IN MALAYSIA¹

**INDICATED IN THE FIRST-LINE SETTING
RYBREVANT[®] + CHEMOTHERAPY:**

A TRANSFORMATIVE AND PRACTICE-CHANGING TREATMENT¹⁻⁶

**THE ONLY TARGETED TREATMENT APPROVED FOR
YOUR PATIENTS WITH EGFR EXON 20 INSERTION-
MUTATED ADVANCED NSCLC:^{1,2}**

**SUPERIOR EFFICACY IN 1L EGFR EXON 20 INSERTION-MUTATED ADVANCED
NSCLC WITH RYBREVANT[®] (AMIVANTAMAB) + CARBOPLATIN AND PEMETREXED
(CHEMOTHERAPY [CT]) VS. CT ALONE**

First-line Treatment Setting

RYBREVANT[®] is now approved in combination with carboplatin and pemetrexed for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with activating EGFR Exon 20 insertion mutations.¹

(PAPILLON Landmark Trial)

Second-Line Treatment Setting

RYBREVANT[®] as monotherapy for the treatment of adult patients with locally advanced or metastatic NSCLC with activating EGFR Exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy.¹

(CHRYSALIS Landmark Trial)

EGFR, epidermal growth factor receptor; NSCLC, non-small cell lung cancer

References: 1. RYBREVANT[®] (Amivantamab) Malaysia Prescribing Information. 2. Zhou C, et al. *N Engl J Med* 2023;389(22):2039–2051. 3. Hendriks LE, et al. *Ann Oncol* 2023;34(4):339–357. 4. Passaro A, et al. *Ann Oncol* 2022;33(5):466–487. 5. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines[®]) for Non-Small Cell Lung Cancer. V.7.2024. Available at: <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1450>. Accessed on November 2024. 6. Vijayaraghavan S, et al. *Mol Cancer Ther* 2020;19(10):2044–2056.

For Healthcare Professionals only. | Further information is available upon request.

Johnson & Johnson

Johnson & Johnson Sdn. Bhd. (Co. No. 3718-D)
Level 8, The Pinnacle, Persiaran Lagoon, Bandar Sunway, 46150 Petaling Jaya, Selangor, Malaysia.
Tel: +603 7661 4500 | Fax: +603 7610 0519
©2025 Johnson & Johnson Sdn. Bhd. All Rights Reserved

Creation Date: July 2025
Creation Code: CP-531918
This material is valid for 1 year from the creation date.

Scan the QR Code for
RYBREVANT[®] Prescribing Information

